US House Committee probes Pfizer, Eli Lilly, Bristol Myers on China trials
The US House Committee has sent letters to Pfizer, Eli Lilly, and Bristol Myers Squibb regarding their drug trials in China. The committee is probing the nature and execution of these clinical trials.

*this image is generated using AI for illustrative purposes only.
The US House Committee has sent letters to Pfizer , Eli Lilly, and Bristol Myers Squibb regarding their drug trials in China. The committee is probing the nature and execution of these clinical trials.
The letters seek detailed information from the pharmaceutical companies. This development highlights increased scrutiny on international clinical trial operations.
Historical Stock Returns for Pfizer
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +3.08% | +6.58% | +3.02% | -2.88% | -16.54% | -17.28% |
How might this scrutiny impact the timeline and approval process for drugs currently in clinical trials in China?
Could increased regulatory oversight lead to higher operational costs for pharmaceutical companies conducting international trials?
What potential legal or financial penalties could Pfizer, Eli Lilly, and Bristol Myers Squibb face if the investigation uncovers misconduct?































